Skip to content
UPBUpstream Bio, Inc.

Earnings

When Upstream Bio, Inc. reports, what it reported each quarter, and how the stock took the results.

15 quarters. Mar 31, 2023 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 25, before the open

Thu, Mar 25, 2027in 128 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 5 – Apr 2

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$668.00K
Revenue, change from a year earlier: Q3 2026 −42.2%, Q2 2026 −17.5%, Q1 2026 +82.7%, Q4 2025 +9.0%
Net income
-$42.46M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$395.00K−42.2% vs Q3 2025

Latest results

  1. Q3 2026Nov 10, 2026, before the openThe release5.9%by the close of Nov 10
    Revenue
    $395.00K
    −42.2%
    Net income
    -$41.19M
    N/M
    EPS
    -$0.75
    N/M
    On November 10, 2026, Upstream Bio, Inc. (the “Company”) announced its financial results and business highlights for the quarter ended September 30, 2026.
  2. Q2 2026Aug 11, 2026, before the openThe release4.9%by the close of Aug 11
    Revenue
    $773.00K
    −17.5%
    Net income
    -$39.70M
    N/M
    EPS
    -$0.73
    N/M
  3. Q1 2026May 13, 2026, before the openThe release+4.6%by the close of May 13
    Revenue
    $1.03M
    +82.7%
    Net income
    -$40.59M
    N/M
    EPS
    -$0.75
    N/M
  4. Q4 2025Mar 26, 2026, before the openThe release+3.6%by the close of Mar 26
    Revenue
    $668.00K
    +9.0%
    Net income
    -$42.46M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 10, 2026 · pre-marketNov 10, 202641 d10-Q$395.00K−42.2%-$0.755.9%
Q2 2026Jun 30, 2026Aug 11, 2026 · pre-marketAug 11, 202642 d10-Q$773.00K−17.5%-$0.734.9%
Q1 2026Mar 31, 2026May 13, 2026 · pre-marketMay 13, 202643 d10-Q$1.03M+82.7%-$0.75+4.6%
FY 2025
Q4 2025derivedDec 31, 2025Mar 26, 2026 · pre-marketMar 26, 202685 d10-K$668.00K+9.0%—+3.6%
Q3 2025Sep 30, 2025Nov 5, 2025 · pre-marketNov 5, 202536 d10-Q$683.00K+12.5%-$0.634.1%
Q2 2025Jun 30, 2025Aug 6, 2025 · pre-marketAug 6, 202537 d10-Q$937.00K+83.7%-$0.74+7.9%
Q1 2025Mar 31, 2025May 6, 2025 · pre-marketMay 6, 202536 d10-Q$566.00K−11.6%-$0.515.4%
FY 2024
Q4 2024derivedDec 31, 2024Mar 12, 2025 · pre-marketMar 12, 202571 d10-K$613.00K——+7.8%
Q3 2024Sep 30, 2024Nov 7, 2024 · pre-marketNov 7, 202438 d10-Q$607.00K−2.3%-$6.96+1.8%
Q2 2024Jun 30, 2024————$510.00K—-$6.50—
Q1 2024Mar 31, 2024————$640.00K—-$4.68—
Earlier years, FY 2023 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 10, 2026454422
10-QAug 11, 2026343417
10-QMay 13, 2026220584
10-KMar 26, 2026126188
10-QNov 5, 2025265713
10-QAug 6, 2025103534
10-QMay 6, 2025063957
10-KMar 12, 2025037621
10-QNov 7, 2024122793

Provenance

ProvenanceData status and checks

Upstream Bio, Inc. · CIK 2022626 · Engraved from SEC EDGAR